Related Experiment Videos
Management of congestive heart failure in the elderly patient
1Hebrew Hospital Home, Bronx, NY 10475, USA.
Insights
Treatment for congestive heart failure (CHF) in elderly patients depends on left ventricular ejection fraction (LVEF). Measuring LVEF is crucial for guiding CHF therapy and improving patient survival.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Congestive heart failure (CHF) in the elderly is frequently caused by coronary artery disease, hypertension, valvular heart disease, and cardiomyopathies.
- Approximately half of elderly patients with CHF present with normal left ventricular ejection fraction (LVEF).
- Accurate LVEF measurement is essential for determining appropriate CHF treatment strategies.
Purpose of the Study:
- To outline the diagnostic and therapeutic approaches for congestive heart failure (CHF) in the elderly population.
- To emphasize the importance of left ventricular ejection fraction (LVEF) assessment in guiding CHF management.
- To review the efficacy and indications of various pharmacological agents in treating CHF with differing LVEF.
Main Methods:
- Review of common etiologies of CHF in elderly patients.
- Discussion of the critical role of LVEF measurement in treatment decisions.
- Analysis of first-line and adjunctive therapies, including diuretics, ACE inhibitors, isosorbide dinitrate/hydralazine, digoxin, calcium channel blockers, and beta-blockers, based on LVEF and patient characteristics.
Main Results:
- Diuretics are the primary treatment for CHF.
- ACE inhibitors reduce mortality in CHF patients with both abnormal and normal LVEF.
- Specific guidelines exist for the use of digoxin, isosorbide dinitrate/hydralazine, calcium channel blockers, and beta-blockers depending on LVEF and clinical presentation.
Conclusions:
- Effective CHF management in the elderly requires addressing underlying and precipitating causes.
- Treatment strategies must be tailored based on LVEF, with specific recommendations for various drug classes.
- Optimizing LVEF and maintaining sinus rhythm are key goals in managing elderly patients with CHF.
Abstract:
Coronary artery disease, hypertension, valvular heart disease, and cardiomyopathies are the commonest causes of CHF in elderly patients. Almost half of elderly patients with CHF have normal LV ejection fraction. LV ejection fraction must be measured before knowing how to treat CHF. Underlying causes of CHF should be treated when possible. Precipitating causes of CHF should be treated. Diuretics are the first-line drug in the treatment of CHF. ACE inhibitors reduce mortality in patients with CHF and should be administered with diuretics to patients with CHF and abnormal or normal LV ejection fraction. Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors. Digoxin should be administered to patients with a rapid ventricular rate associated with supraventricular tachyarrhythmias. Digoxin should be administered to patients with CHF in sinus rhythm and abnormal LV ejection fraction that does not respond to diuretics plus ACE inhibitors or in patients unable to tolerate ACE inhibitors or other vasodilator therapy. Digoxin should not be given to patients with CHF in sinus rhythm with normal LV ejection fraction. Calcium channel blockers are contraindicated in patients with CHF and abnormal LV ejection fraction but may be used to treat CHF with normal LV ejection fraction. The use of beta blockers in the treatment of CHF with abnormal LV ejection fraction is experimental. However, beta blockers might improve clinical symptoms in patients with CHF and normal LV ejection fraction by slowing heart rate, thereby increasing LV diastolic filling time and increasing LV end-diastolic volume. Maintenance of sinus rhythm will also increase LV diastolic filling time in patients with CHF and normal LV ejection fraction.